A Multicenter, Open-Label, Dose Escalation Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematologic Malignancies.

Trial Profile

A Multicenter, Open-Label, Dose Escalation Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematologic Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2011

At a glance

  • Drugs Anti-HGF monoclonal antibody L2G7 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 01 Dec 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 01 Dec 2011 Actual patient number is 27 according to ClinicalTrials.gov.
    • 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top